종목/NVNO
enVVeno Medical Corporation
예정된 실적 발표가 아직 잡히지 않았습니다.
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 4월 29일 (수) | 2026 Q1 | $-0.24 | — | — | — | — |
| 100% (4/4) |
| UNH | 유나이티드헬스 | 389B | +8.9% | 75% (3/4) |
| MRK | 머크 | 318B | +16.0% | 100% (4/4) |
애널리스트 의견이 수집되지 않았습니다.